HPV16 E6 seropositivity among cancer-free men with oral, anal or genital HPV16 infection

Daniel C. Beachler; Tim Waterboer; Christine M. Pierce Campbell; Donna J. Ingles; Krystle A. Lang Kuhs; Alan G. Nyitray; Allan Hildesheim; Michael Pawlita; Aimée R. Kreimer; Anna R. Giuliano

doi:10.1016/j.pvr.2016.07.003

HPV16 E6 seropositivity among cancer-free men with oral, anal or genital HPV16 infection

Daniel C. Beachler, Tim Waterboer, Christine M. Pierce Campbell, Donna J. Ingles, Krystle A. Lang Kuhs, Alan G. Nyitray, Allan Hildesheim, Michael Pawlita, Aimée R. Kreimer, Anna R. Giuliano

Research output: Contribution to journal › Article › peer-review

10 Scopus citations

Abstract

Antibodies against the Human papillomavirus 16 (HPV16) E6 oncoprotein appear years prior to clinical diagnosis of anal and oropharyngeal cancer, but whether they develop around the time of HPV infection is unclear. Serum samples from 173 cancer-free men from the Human Papillomavirus Infection in Men (HIM) Study were tested for HPV antibodies and DNA. HPV16 E6 seropositivity was low among men with oral HPV16-infection (1/28; 3.6%, 95%CI=0.0–18.4%), anal HPV16-infection (1/61; 1.6%, 95%CI=0.0–8.8%), and 24-month persistent genital HPV16-infection (1/84; 1.2%, 0.0–6.5%). This suggests E6 seroconversion may not occur around the time of oral, anal, or genital HPV16 acquisition.

Original language	English
Pages (from-to)	141-144
Number of pages	4
Journal	Papillomavirus Research
Volume	2
DOIs	https://doi.org/10.1016/j.pvr.2016.07.003
State	Published - Dec 1 2016

Bibliographical note

Publisher Copyright:
© 2016

Keywords

Anal cancer
HPV
HPV16 E6 seropositivity
Oropharyngeal cancer
Penile cancer

ASJC Scopus subject areas

Virology
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.pvr.2016.07.003

Cite this

@article{1e34ab96b1b948b9b9fd262fda812aa6,

title = "HPV16 E6 seropositivity among cancer-free men with oral, anal or genital HPV16 infection",

abstract = "Antibodies against the Human papillomavirus 16 (HPV16) E6 oncoprotein appear years prior to clinical diagnosis of anal and oropharyngeal cancer, but whether they develop around the time of HPV infection is unclear. Serum samples from 173 cancer-free men from the Human Papillomavirus Infection in Men (HIM) Study were tested for HPV antibodies and DNA. HPV16 E6 seropositivity was low among men with oral HPV16-infection (1/28; 3.6%, 95%CI=0.0–18.4%), anal HPV16-infection (1/61; 1.6%, 95%CI=0.0–8.8%), and 24-month persistent genital HPV16-infection (1/84; 1.2%, 0.0–6.5%). This suggests E6 seroconversion may not occur around the time of oral, anal, or genital HPV16 acquisition.",

keywords = "Anal cancer, HPV, HPV16 E6 seropositivity, Oropharyngeal cancer, Penile cancer",

author = "Beachler, {Daniel C.} and Tim Waterboer and {Pierce Campbell}, {Christine M.} and Ingles, {Donna J.} and {Lang Kuhs}, {Krystle A.} and Nyitray, {Alan G.} and Allan Hildesheim and Michael Pawlita and Kreimer, {Aim{\'e}e R.} and Giuliano, {Anna R.}",

note = "Publisher Copyright: {\textcopyright} 2016",

year = "2016",

month = dec,

day = "1",

doi = "10.1016/j.pvr.2016.07.003",

language = "English",

volume = "2",

pages = "141--144",

}

TY - JOUR

T1 - HPV16 E6 seropositivity among cancer-free men with oral, anal or genital HPV16 infection

AU - Beachler, Daniel C.

AU - Waterboer, Tim

AU - Pierce Campbell, Christine M.

AU - Ingles, Donna J.

AU - Lang Kuhs, Krystle A.

AU - Nyitray, Alan G.

AU - Hildesheim, Allan

AU - Pawlita, Michael

AU - Kreimer, Aimée R.

AU - Giuliano, Anna R.

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Antibodies against the Human papillomavirus 16 (HPV16) E6 oncoprotein appear years prior to clinical diagnosis of anal and oropharyngeal cancer, but whether they develop around the time of HPV infection is unclear. Serum samples from 173 cancer-free men from the Human Papillomavirus Infection in Men (HIM) Study were tested for HPV antibodies and DNA. HPV16 E6 seropositivity was low among men with oral HPV16-infection (1/28; 3.6%, 95%CI=0.0–18.4%), anal HPV16-infection (1/61; 1.6%, 95%CI=0.0–8.8%), and 24-month persistent genital HPV16-infection (1/84; 1.2%, 0.0–6.5%). This suggests E6 seroconversion may not occur around the time of oral, anal, or genital HPV16 acquisition.

AB - Antibodies against the Human papillomavirus 16 (HPV16) E6 oncoprotein appear years prior to clinical diagnosis of anal and oropharyngeal cancer, but whether they develop around the time of HPV infection is unclear. Serum samples from 173 cancer-free men from the Human Papillomavirus Infection in Men (HIM) Study were tested for HPV antibodies and DNA. HPV16 E6 seropositivity was low among men with oral HPV16-infection (1/28; 3.6%, 95%CI=0.0–18.4%), anal HPV16-infection (1/61; 1.6%, 95%CI=0.0–8.8%), and 24-month persistent genital HPV16-infection (1/84; 1.2%, 0.0–6.5%). This suggests E6 seroconversion may not occur around the time of oral, anal, or genital HPV16 acquisition.

KW - Anal cancer

KW - HPV

KW - HPV16 E6 seropositivity

KW - Oropharyngeal cancer

KW - Penile cancer

UR - http://www.scopus.com/inward/record.url?scp=84980317614&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84980317614&partnerID=8YFLogxK

U2 - 10.1016/j.pvr.2016.07.003

DO - 10.1016/j.pvr.2016.07.003

M3 - Article

AN - SCOPUS:84980317614

VL - 2

SP - 141

EP - 144

JO - Papillomavirus Research

JF - Papillomavirus Research

ER -

HPV16 E6 seropositivity among cancer-free men with oral, anal or genital HPV16 infection

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this